Safiye Günes SAGER, Yakup ÇAĞ

Determination of the factors that cause valproic acid resistance in the pediatric juvenile myoclonic epilepsy cohort

Juvenile myoclonic epilepsy (JME) has an approximate prevalence of 18%–20% among idiopathic generalized epilepsy types. Valproic acid (VPA) is the first line treatment of JME; however, resistance to VPA was detected as the most important prognostic entity for refractory seizures. The present study aims to determine the factors that induce VPA resistance in pediatric patients with JME. Patients between the ages of 10 and 18 who were diagnosed with JME were examined retrospectively. The groups with VPA resistant and non-resistant group were statistically analyzed. Total of 62 patients diagnosed with JME, 41 (66.1%) of them were female. The average age was 15.48±2.11 years. VPA resistance was detected in 21(33.8%) of our patients. Seizure onset age of patients younger than 15 years, presence of febrile seizure (FS), photosensitivity, seizure type, seizures occurring both at day and night, and epileptic discharge longer than 3 seconds during EEG were found to be statistically significant risk factors for the development of VPA resistance. Close monitoring of individuals with these risk factors is recommended for VPA resistance.

PDF

___

1. Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy Behav. 2013;1:15-7.
2. Yacubian EM. Juvenile myoclonic epilepsy: Challenges on its 60th anniversary. Seizure. 2017;44:48-52.
3. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011;4:47-62.
4. Gilsoul M, Grisar T, Antonio V, et al. Subtle brain developmental abnormalities in the pathogenesis of juvenile myoclonic epilepsy. Front Cell Neurosci. 2019;13:433.
5. Martins da Silva A, Leal B. Photosensitivity and epilepsy: Current concepts and perspectives-A narrative review. Seizure. 2017;50:209-18.
6. Genton P, Thomas P, Kasteleijn-Nolst Trenité DG, et al. Clinical aspects of juvenile myoclonic epilepsy. Epilepsy Behav. 2013;281:8-14.
7. Gelisse P, Genton P, Thomas P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry. 2001;70:240-3.
8. Gesche J, Khanevski M, Solberg C, Beier CP. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies. Epilepsia. 2017;58:64-9.
9. Amrutkar C, Riel-Romero RM. Juvenile myoclonic epilepsy. 2020;10. Treasure Island (FL): StatPearls Publishing; 2021.PMID:30725794.
10. Holtkamp M, Senf P, Kirschbaum A, Janz D. Psychosocial long-term outcome in juvenile myoclonic epilepsy. Epilepsia. 2014;55:1732-8.
11. Chen Y, Chen J, Chen X, Wang R, et al. Predictors of outcome in juvenile myoclonic epilepsy. Risk Manag Healthc Policy. 2020:19;13:609-13.
12. Lin JJ, Dabbs K, Riley JD, Jones JE, et al. Neurodevelopment in new-onset juvenile myoclonic epilepsy over the first 2 years. Ann Neurol. 2014;76:660-8.
13. Chan CK, Low JS, Lim KS, et al. Whole exome sequencing identifies a novel SCN1A mutation in genetic (idiopathic) generalized epilepsy and juvenile myoclonic epilepsy subtypes. Neurol Sci. 2020;41:591-8.
14. Santos BPD, Marinho CRM, Marques TEBS, et al. Genetic susceptibility in Juvenile Myoclonic Epilepsy: Systematic review of genetic association studies. PLoS One. 2017;21;12:e0179629.
15. Senf P, Schmitz B, Holtkamp M, Janz D. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology. 2013;81:2128-33.
16. Appleton R, Beirne M, Acomb B. Photosensitivity in juvenile myoclonic epilepsy. Seizure. 2000;9:108-11.
17. Moeller F, Siebner HR, Wolff S, Muhle H, et al. Mapping brain activity on the verge of a photically induced generalized tonic-clonic seizure. Epilepsia 2009;50:1632–7.
18. Menini C, Naquet R. Myoclonia: From the myoclonia of Papio papio to various human myoclonias. Rev Neurol (Paris) 1986;142:3–28.
19. Groppa S, Moeller F, Siebner H, Wolff S, et al. White matter microstructural changes of thalamocortical networks in photosensitivity and idiopathic generalized epilepsy. Epilepsia 2012;53:668–76.
20. Verrotti A, Tocco AM, Salladini C, Latini G, et al. Human photosensitivity: from pathophysiology to treatment. Eur J Neurol. 2005;12:828-41.
21. Badawy RA, Macdonell RA, Jackson GD, Berkovic SF. Why do seizures in generalized epilepsy often occur in the morning? Neurology. 2009;73:218- 22.
22. Uchida CG, de Carvalho KC, Guaranha MS, et al. Phenotyping juvenile myoclonic epilepsy. Praxis induction as a biomarker of unfavorable prognosis. Seizure. 2015;32:62-8.
23. Japaridze G, Kasradze S, Lomidze G, et al. Focal EEG features and therapeutic response in patients with juvenile absence and myoclonic epilepsy. Clin Neurophysiol. 2016;127:1182-87.